Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00237263 · ClinicalTrials.gov registry record · Phase 2
An Extension Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off. This Study is Not Recruiting in the United States
A Phase 2 study, sponsored by Novartis.
- Completed
- Registry status
- Phase 2
- Development phase
- 285
- Enrollment target
NCT00237263 is a Phase 2 study that has completed, run by Novartis. The registered enrollment target is 285 participants.
The verdict
NCT00237263, a Phase 2 study, has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 285 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of the long-term treatment of entacapone in patients with Parkinson's disease with end-of-dose wearing-off. This study is not recruiting patients in the United States.
Interventions
- DRUG Entacapone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 285 participants |
| Start Date | 2003-02 |
| Est. Completion | 2007-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00237263
The ClinicalTrials.gov registry entry for NCT00237263 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 285 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Entacapone is the first listed.
NCT00237263 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00237263 about?
NCT00237263 is a clinical study titled "An Extension Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off. This Study is Not Recruiting in the United States". The purpose of this study is to evaluate the safety and efficacy of the long-term treatment of entacapone in patients with Parkinson's disease with end-of-dose wearing-off. This study is not recruiting patients in the United States.
What is the current status of trial NCT00237263?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 285 participants. The study started on 2003-02. Estimated completion is 2007-07.
What interventions are being tested in trial NCT00237263?
The interventions under investigation include: Entacapone (DRUG).
Who is sponsoring clinical trial NCT00237263?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.